Biopharma Daily Stock Updates - 01/20/21

$XBI $154.13 (-0.09%) 📉

COVID:

$PFE (-0.65%) & $BNTX (-1.40%) - Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

https://biontechse.gcs-web.com/news-releases/news-release-details/pfizer-and-biontech-publish-results-study-showing-covid-19

$GRTS (+14.46%) - Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

http://ir.gritstoneoncology.com/news-releases/news-release-details/gritstone-and-genevant-sciences-announce-license-agreement-covid

PIPELINE:

$OCUL (-0.85%) - OCULAR THERAPEUTIX™ PRESENTS INTERIM TOPLINE DATA FROM THE PHASE 1 CLINICAL TRIAL OF OTX-TIC IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION AT THE 10TH ANNUAL GLAUCOMA 360 NEW HORIZONS FORUM

http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-presents-interim-topline-data-phase-1

$AZN (-0.63%) - EU approval

https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-eu-for-breast-cancer.html

$ARQT (-1.78%) - Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

https://investors.arcutis.com/news-releases/news-release-details/arcutis-advance-topical-roflumilast-foam-arq-154-phase-3

$ONCR (-5.00%) - ONCORUS ANNOUNCES PUBLICATION OF PRECLINICAL DATA DEMONSTRATING POTENT SYSTEMIC ANTITUMOR ACTIVITY OF ITS CLINICAL STAGE ONCOLYTIC HERPES SIMPLEX VIRAL IMMUNOTHERAPY PRODUCT CANDIDATE ONCR-177

https://investors.oncorus.com/news-releases/news-release-details/oncorus-announces-publication-preclinical-data-demonstrating

FMTX (-2.11%) - Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

https://ir.formatherapeutics.com/news-releases/news-release-details/forma-therapeutics-announces-first-patient-dosed-phase-1

FINANCIAL:

$TCRR (-2.85%) - Announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share.

https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-announces-pricing-public-offering-1400-million

$ONCS (-5.11) - OncoSec Medical Announces Proposed Public Offering of Common Stock

https://ir.oncosec.com/press-releases/detail/2074/oncosec-medical-announces-proposed-public-offering-of

$ACRX (-17.02%) - AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock

https://ir.acelrx.com/news-releases/news-release-details/acelrx-announces-pricing-275-million-public-offering-common

$ACRS (-4.57%) - Pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.

http://investor.aclaristx.com/news-releases/news-release-details/aclaris-announces-pricing-public-offering-common-stock-2

$SYRS (-11.97%) - Priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share https://ir.syros.com/press-releases/detail/212/syros-announces-pricing-of-75-6-million-public-offering-of
 https://ir.syros.com/press-releases/detail/212/syros-announces-pricing-of-75-6-million-public-offering-of

$FULC (+18.93%) - Priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share

https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-pricing-public-offering-common